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   Biodegradable poly(L-lactic acid) and poly(D, L-lactic acid) microspheres incorporating anti-cancer 
drugs, adriamycin a d cisplatin, were prepared by the solvent evaporation method. Effects of several 
variables on the drug release were studied and it was found that the drug distribution in the matrix was 
the most important, which in turn depended on the solubility ofthe drug in the matrix polymer. 
Release rates of the drug could be altered to some xtents by changing the drug loading, the molecular. 
weight and chemical composition f the matrix polymer, and the drug/polymer mixing method. 
Especially, the mechanical mixing could greatly reduce the drug burst seen in an early stage of the 
release. 
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                         INTRODUCTION 
   In connection with achievement of maximum bioavailability of conventional drugs 
with minimum side-effects, new drug delivery systems (DDS) have attracted much 
attention.' Controlled or sustained release of drugs is one of these concenpts. To 
develop the systems, polymeric materials probably are essential as matrix which slowly 
releases the drug incorporated in its interior. 
   We have been studyingDDS using the polylactides which include poly(lactic acid), 
poly(glycolic acid), and their copolymers. These polymers belong to the most well-
known biodegradable polymers which are first hydrolyzed without enzymes and then 
metabolized in the body.2) They have been used as surgical sutures and have been 
proved to be nontoxic.3) Moreover, their degradation rate can be regulated by chang-
ing their molecular weight, chemical composition, and crystallinity. Therefore, poly-
lactides seem to be very promising as matrix for DDS. Indeed, a large number of 
studies which utilize these polymers have been intensively done in the DDS field in 
recent years,4-8) but their basic data and informations for drug release are insufficient 
from the viewpoint of polymer science. 
   The present work was carried out in an attempt to prepare poly(lactic acid) 
microspheres containing anti-cancer drugs with different physical properties. 
                        EXPERIMENTAL 
Materials 
   Doxorubicin hydrochloride (adriamycin, ADR) and cis-dichlorodiamine platinum 
pF13 — EBove, ircA, a *A : Research Center for Medical Polymers and Biomaterials, 
Kyoto University, 53 Syogoin Kawahara-cho, Sakyo-ku, Kyoto 606, Japan.-
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(II)(cis-platin, CDDP) were donated by Kyowa Hakko Co., Tokyo, Japan, and Nihon 
Kayaku Co., Tokyo, Japan, respectively, and used without purification. Their chemical 
structures, solubility in water and methylene chloride, and molecular weight are 
represented in Table 1. 
                    Table 1. The Physical properties of drugs used. 
Adriamycin Cisplatin 
                               (ADR) (COOP) 
0 OH                                                                 COCH2OH 
                                                       OH 
0CH,0 OHH 0C ,Pt'                           0C l sNA           CC 
                                                  H0
NH, H 
 in water good 1 mg/ml 
                          solubility inCH2Cl2 2-3/mlnegligisW9 sm                                                                   all
molecular weight 579.99300.05 
   Poly(lactic acid)s were synthesized by polycondensation of L-lactic acid or D,L-
lactic acid at 180°C under a reduced pressure without any catalyst. Poly(lactic acid)s of 
different molecular weights were obtained by changing the polymerization time. For 
removal of the monomers, the oligomeric products were dissolved in methylene chloride 
or methanol, followed by precipitation with methanol or water, respectively. The 
weight average molecular weights of the oligomers were determined by gel permeation 
chromatography (GPC) using standard polystyrenes. Other chemicals were of guaran-
teed grade and used without further purification. 
Microsphere Preparation 
   The microspheres containing ADR or CDDP were prepared by the solvent eva-
poration method?) The schematic presentation is given in Figure 1. Briefly, one gram 
of poly(lactic acid) was dissolved in 10 ml of methylene chloride in the case of (O/W) 
method and in 10 ml of acetonitrile in the case of (0/0) method. A given amount of 
drugs was added to these solutions and then suspended homogeneously by sonication. 
The suspensions were added dropwise under agitation to water containing 2 wt % 
poly(vinyl alcohol)(PVA), or to silicone oil containing 0.1 wt % soy bean lecithin. PVA 
and lecithin were used as emulsifier. The temperature of emulsions was raised to 30 or 
45°C to allow evaporation of methylene chloride or acetonitrile, respectively. Follow-
ing evaporation of the solvents, the microspheres were collected by centrifugation, 
washed three times with cold distilled water or petroleum ether, and then lyophilized. 
Characterization of Microspheres 
   To determine. the ADR content of the microspheres, a weighed amount of micros-
pheres was dissolved in 1 ml of methylene chloride and the solution obtained was 
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                   Figure1. Scheme of solvent evaporation method. 
diluted to 100 ml with methanol. A fluorescence spectrophotometer (Hitachi, Model 
650 10-S, Tokyo, Japan) was used to determine the ADR concentration at the excitation 
wavelength of 470 nm and the emission wavelength of 580 nm. The microsphere 
containing CDDP was dissolved in 1 ml of chloroform and the organic solution was 
extracted with the same volume of distilled water. The CDDP concentration of the 
extract was determined by HPLC assay.10) The size of microspheres was determined 
by observation with scanning electron microscopy (SEM, Hitachi Model S-450, Tokyo, 
Japan). SEM was also used to follow the hydrolytic degradation of microspheres. 
In Vitro Release Test 
   A weighed amount of microspheres was suspended in a given amount of Tris 
buffer solution at pH 7.4 and the resulting suspension was stored in a vial. For the in 
vitro release study, the vial was immersed in a shaker bath kept at 37°C and the release 
medium was periodically removed, the same amount of the fresh medium being added 
to the vial. The amount of ADR and CDDP released into the medium was measured 
using the fluorescence spectrophotometer and HPLC, respectively, as described above. 
Bioactivity of ADR released from the microspheres was evaluated by bioassay using 
Bacillus subtilis ATCC 6633.11) 
                     RESULTS AND DISCUSSION 
Effects of Preparation Conditions on Drug Release. 
   Figure 2 shows the in vitro release profiles of ADR from the poly(L-lactic acid) 
microspheres with different drug contents. The molecular weights of PLA were all 
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       Figure 2. Release profiles of ADR from ADR/L-lactic acid oligomer microspheres (Mw=6,100). 
               (0) 24.6 pg-ADR/mg-sphere, (D) 14.4 pg-ADR/mg-sphere, (.A) 5.3pg-ADR/mg-sphere. 
      6,100. Amounts of ADR released from 10 mg of each microsphere are shown as 
      cumulative microgram. Retention of bioactivities of ADR released was confirmed by 
      bioassay. Initial loadings of ADR were varied by changing the ADR amount used for 
      the preparation of the microspheres. Weight percentage of ADR trapped in the 
      microspheres was as high as 50 to 70%. 
        ADR is partially soluble in methylene chloride from which poly(lactic acid) 
      solution was prepared and hence some amounts of ADR can be entrapped in the 
      microspheres, leading to the sustained release of ADR from the microspheres. In the 
      case of CDDP, however, it is very difficult to, prepare the CDDP microsphere using the 
      0/W solvent evaporation method because of the poor solubility of CDDP in organic 
      solvents. The CDDP drug crystals tend to diffuse out from the organic phase to the 
      water phase, resulting in quite low trapping of CDDP in the microsphere, mostly less 
      than 10 %. In order to achieve high trapping of CDDP, the 0/0 method was applied 
      to the preparation of CDDP microspheres. The 0/0 method essentially does not 
      allow the transfer of CDDP to the outer phase of silicone oil. Indeed, almost 100% of 
     CDDP could be entrapped in the microsphere by this method, although 80% of CDDP 
      of the initial loading burst out from this microsphere in one hour in the beginning of the 
      release test. Probably, this is due to heterogeneous distribution of CDDP in the 
      polymer matrix, as the CDDP drug crystals dispersed in the matrix seem to form 
      continuously connecting channels which must enable penetration of the outer aqueous 
      medium into the microsphere, resulting in quite fast leakage of the drug from the 
      microshere. Spenlehauer et al. also evaluated the effect of preparation condition of the 
O/W solvent evaportion method on release profiles of poly(D, L-lactide) microspheres 
      containing CDDP.12? They reported that the drug trapping was markedly enhanced by 
      saturation of the outer aqueous phase with CDDP. 
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Figure 4. Release profile of CDDP from CDDP/ L-lactic acid oligomer microsphere (law =13,000 
        2.0 pg-CDDP/mg-sphere). 
   To improve the CDDP entrapping and the release profile, we applied the (W/O)/W 
type solvent evaporation method as shown in Figure 3. The CDDP microspheres 
involving the aqueous microphase of a diameter from 1 to 10 ,rm7, was prepared by this 
method. The diameter of the final microspheres was 10 to 100 ,um. The release profile 
of CDDP from this microsphere is shown in Figure 4. The internal aqueous microph-
ase containing gelatin and the wall material made of poly(lactic acid) successfully 
retained the drug, but the quite low solubility of CDDP in water phase limited the initial 
drug loading in the microspheres even when the internal aqueous microphase was 
saturated with CDDP higher than 1(w/w)% CDDP by this (W/O)/W method. A new 
method is necessary to prepare the CDDP microspheres which have higher loadings 
and longer release periods. 
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   The  O/W type solvent evaporation method was first described by Beck et al. for 
preparation of poly(lactic acid) microspheres containing progesterone, a steroid 
hormone-9) This method will be appropriate for the preparation of the microspheres 
incorporating highly lipophilic drugs such as steroids and aclacinomycin.13) Slightly 
lipophilic drugs such as adriamycin are also applicable to this method as above 
described, but the trapping efficiency and the release profile may be not so good as for 
highly lipophilic drugs. Highly hydrophilic drugs such as CDDP and many other 
drugs are not appropriate for the 0/W method. It appears that an 0/0 method, a 
(W/O)/W method, or more improved ones are should be improved for this group of 
drugs. Our results show that physical properties, especially solubility of the drugs are 
the most important factor for the preparation of poly(lactic acid) microspheres contain-
ing these drugs. 
Effect of Matrix Polymer on Drug Release 
   As shown in Figure 2, the initial loading of ADR microspheres affects the release 
profile, but the initial content of ADR in the microspheres is not proportional to the 
release amount. On the other hand, the degradation rate of the poly(lactic acid) is 
likely to influence the release rate of drugs. 
   Therefore, we studied the effect of molecular weight of the poly(lactic acid)s on the 
drug release. Table 2 represents the molecular weights of various poly(lactic acid)s 
used for the microsphere preparation, together with the loadings and trapping efficien-
cies of ADR in the microspheres prepared at the ADR/polymer ratio of 0.02 (w/w). 
The amount of ADR loaded in the resulting microspheres varied with the molecular 
weight of the polymer, probably because the microsphere was prepared with the O/W 
method which allowed partial dissolution of ADR into the outer aqueous phase. To 
evaluate the effect of molecular weight of the polymer on the release profiles, the 
microspheres which had almost the same ADR contents were selected out of several 
samples. Release profiles of ADR from the microspheres of poly(L-lactic acid)s with 
different molecular weights are shown in Figure 5. The release rate is reduced as the 
molecular weight increases, indicating that the release rate is controllable by changing 
the degradation rate of the matrix polymer. The results obtained with the poly(D, 
L-lactic acid) microspheres are shown in Figure 6. Generally speaking, the polymer 
from optically active L-lactic acid is crystalline, whereas the polymer from racemic D, 
L-lactic acid is amorphous, so far as the molecular weight is sufficiently high. Oli- 
        Table 2. Drug weights and trapping in microspheres. 
    LA oligomerDrug loaded% trapped (
pg-ADR/mg-sphere) 
   L-3,40017.5688.0 
   L-6,10010.1551.2 
   L-13,0007.1136.0 
   D, L-3,30013.2566.7 
   D, L-6,4006.2131.0 
   D, L-9,6006.0330.6 
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Figure 5. Release profililes of ADR from ADR/L-lactic acid oligomer microspheres. (o) Mw=3,400 
        (14.1 ug-ADR/mg-sphere), (•) Mw=6,100 (14.4 pg-ADR/mg-sphere), (o) Mw=13,000 (15.6 
pg-ADR/mg-sphere). 
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Figure 6. Release profiles of ADR from ADR/D, L-lactic acid oligomer microspheres. (0) Mw=3,300 
(16.1,g-ADR/mg-sphere), (.) Mw=6,400 (17.2 pg. ADR/ mg-sphere), (z) Mw=9,600 (21.5 
,ug-ADR/mg-sphere). 
gomeric poly(lactic acid)s used in this study may have low degrees of crystallinity and 
the difference of degradation rate between L- and D, L-polymer may be so small that 
the difference of the release rate between the two polymers must be quite small as 
shown in Figure 6. 
   We have also investigated the effect of monomer composition in poly(L-lactic 
acid-co-glycolic acid) on the release profiles of a fluorescent (rhodamine 6GX) from the 
copolymer microspheres.14) The largest release rate was realized at the glycolic acid 
composition of 50 mole%, in accordance with the most rapid degradation of the 
copolymer. This result is in good agreement with that shown in Figure 5, again 
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suggesting that the degradation rate of the matrix polymer affects the release rate of 
drugs from the microsphere. However, in the case of ADR, the spacial distribution of 
the drug in the microsphere may not be sufficiently homogeneous. The small differ-
ence of the release profiles between poly(L-lactic acid) and poly(D, L-lactic acid) as 
described above may be also due to this distribution difference. In order to learn in 
more detail the effect of nature of the matrix polymer on the release profiles, a highly 
lipophilic drug such as aclacinomycin13), which can be successfully entrapped in the 
poly(lactic acid) microspheres, may be more appropriate. 
Morphological Change of Microspheres during Hydrolysis 
   Figure 7 shows the morphological change of the ADR microsphere accompanying 
the in vitro hydrolytic degradation. The microsphere was prepared from poly(L-lactic 
acid) with a molecular weight of 3,400. SEM observation reveals that the microsphere 
undergoes the hydrolytic degradation and produces small pores and cracks which 
probably are responsible for the release of the drug. After hydrolysis for 7 days, the 
microsphere did not have spherical shape any more, but still colored red due to the 
existence of ADR. This fact implies that the release of ADR after 7 to 10 days as 
shown in Figures 2, 6, and 7 are mostly caused by the degradation of the matrix 
polymer. 
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Effect of Drug Distribution on the Release 
   As described above, large amounts of drugs loaded always leak out from the 
microspheres within first several hours. This phenomenon is called the "burst" release. 
In order to elucidate the cause of this phenomenon, we fabricated lactic acid oligomer 
beads containing ADR by the following method. One gram of lactic acid oligomer was 
melted on a steel plate heated to 60-70°C and then mixed mechanically with 10 mg of 
ADR. The apparently homogeneous mixture was shaped into spherical beads as large 
as 2 mm in diameter. The release profile from the ADR beads is shown in Figure 8. 
The initial burst is greatly reduced in comparison with that of microspheres. The 
relation between the release amount of ADR and the square root of the release period is 
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Figure 8. Release profiles of ADR from ADR/L-lactic acid oligomerbeads (0=2 mm, ADR loading = 
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Figure 9. Higuchi plot of ADR release from ADR/L-lactic acid oligomer beads. (z) Mw=3,400, (•) Mw=4,700, (0) Mw= 6,100. 
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the drug in the beads is more homogeneous than that of the ADR microspheres. In 
addition, it appears that the ADR microspheres have many pores and channels in the 
matrix. It follows that the most effective microsphere preparation from polylactides 
without the minimum burst release depends on how homogeneously the hydrophilic 
drugs are distributed in the microsphere. 
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